Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ViTAL-PH
NCT06846554Phase 2Recruiting
- Sponsor
- Apollo Therapeutics
- Start
- Apr 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of AP13 in pulmonary arterial hypertension (PAH), Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD), sponsored by Apollo Therapeutics. Started Apr 2025; status: recruiting.
02
Drugs
AP13
03
Conditions
pulmonary arterial hypertension (PAH)Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD)
Beyond the preview
Go deeper on NCT06846554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846554.